What Does the Future Hold and What Will It Mean for Patients?

The Standard of Care is Changing Again

Why Do We Need a New Standard of Care?

The Ideal Treatment for Chronic HCV Infection

Agents in Phase 3 HCV Treatment Pipeline Not Approved for Use in the US

Sofosbuvir

VALENCE: Sofosbuvir + RBV for 24 Weeks in G3 HCV Infection

NEUTRINO Study: SVR12 by HCV Genotype

NEUTRINO Study: Virologic Response by Cirrhosis Status

Simeprevir in Patients With G1 HCV Infection

Shortened Therapy in 85% to 91%

Q80K: A Major Issue

On the Road to IFN-free Therapy

On the Road to IFN-free Therapy (cont)

One Size Fits All vs Tailored Regimen

Second-Generation Protease Inhibitor-based, IFN-free Regimens

PI + NS5A in Prior Null Responders

IFN-free Regimens Combining 3 DAA Drug Classes

More Potent Protease Inhibitors in Phase 2 Clinical Trials

What Does It Mean for Patients?

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)